Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Explainable Artificial Intelligence to Predict Neurocognitive Disorder Progression in Multiple Sclerosis Using MRI and Clinical Data.
The central role of mitochondrial dysfunction in neurodegeneration: implications for therapy.
Evaluation of AI Chatbot Responses to a Standardized Patient Query on Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Cross-Sectional Content Analysis.
Medical evaluation of first presentation of psychotic symptoms in children and adolescents.
Longitudinal retinal microvascular changes and their association with white matter hyperintensities in neuromyelitis optica spectrum disorder.
Isoform-specific roles of QKI-6 and QKI-7 direct Schwann cell lineage progression and enhance peripheral nerve regeneration.
MicroRNA profiles in multiple sclerosis: A review of the literature.
EBV viral load and miR-BART10-3p expression in multiple sclerosis: A case-control study.
How are interleukin-6 receptor antagonists shaping the future of neuromyelitis optica spectrum disorder?
Piezo1 in the central nervous system: decoding the mechanical signature of neuroinflammation.
On the optimal sodium correction rate in hyponatraemia and clinical outcome: a meta-analysis.
Association Between Motor Pathway Damage and Motor Deficit in Upper and Lower Limb in People With MS.
Tick-Borne Infection as a Precipitant of Guillain-Barré Syndrome: A Case of Lyme Neuroborreliosis.
PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis.
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.
Cholesterol in Myelin: Supply Routes, Pathological Consequences, Biophysical Governance, and Future Frontiers.
Neuronal injury and axonal degeneration: Pathologic mechanisms and findings beyond Wallerian changes.
Paeoniflorin as a candidate disease-modifying therapy for diabetic peripheral neuropathy: mechanisms, exposure challenges, and translational priorities.
Intrathecal IgM species as potential prognostic biomarkers in relapsing-remitting multiple sclerosis.
MAL/SPP1 axis drives tumor proliferation and immune evasion via JAK2/STAT3 and MHC class Ib in breast cancer.
Global landscape of neuromyelitis optica spectrum disorder clinical trials: trends in therapies, geography, and outcomes.
Risk Factors for Urinary Tract Infections in Patients with Multiple Sclerosis.
Mining online peer support communities to understand treatment side effects in Multiple Sclerosis.
Evaluation of the DTI-ALPS index in neuromyelitis optica spectrum disorder: a cross-sectional study of its correlation with disease duration and disability.
β-oxidation-mediated differentiation of effector CD4 T cells in the lung enhances neuroinflammation.
Pages
« first
‹ previous
…
1013
1014
1015
1016
1017
1018
1019
1020
1021
…
next ›
last »